The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid

Journal of Neuroimmunology

Volumn 209, Issue 1-2, 2009, Pages 57-64

  Mueller, André M ^a,b   Pedré, Xiomara ^a   Killian, Stephan ^a   David, Monique ^b   Steinbrecher, Andreas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Multiple Sclerosis Research Center of New York Inc   (United States)

Author keywords

DcR3; EAE; FasL; IL 17; LIGHT; TL1A

Indexed keywords

DECOY RECEPTOR 3; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPH NODE CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TH17 CELL;

ANIMALS; ANTIGENS, CD95; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 64549154851     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.01.024     Document Type: Article

References (33)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev., Immunol. 3 (2003) 745-756
2. Bettelli E., Korn T., Oukka M., and Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 453 (2008) 1051-1057
3. Brunner T., Wasem C., Torgler R., Cima I., Jakob S., and Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin. Immunol. 15 (2003) 167-176
4. Chang Y.C., Hsu T.L., Lin H.H., Chio C.C., Chiu A.W., Chen N.J., Lin C.H., and Hsieh S.L. Modulation of macrophage differentiation and activation by decoy receptor 3. J. Leukoc. Biol. 75 (2004) 486-494
5. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., and Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116 (2006) 1317-1326
6. Fayad R., Brand M.I., Stone D., Keshavarzian A., and Qiao L. Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. Eur. J. Immunol. 36 (2006) 2215-2222
7. Hsu T.L., Chang Y.C., Chen S.J., Liu Y.J., Chiu A.W., Chio C.C., Chen L., and Hsieh S.L. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J. Immunol. 168 (2002) 4846-4853
8. Hsu T.L., Wu Y.Y., Chang Y.C., Yang C.Y., Lai M.Z., Su W.B., and Hsieh S.L. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J. Immunol. 175 (2005) 5135-5145
9. Igney F.H., and Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71 (2002) 907-920
10. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., and Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006) 1121-1133
11. Ka S.M., Sytwu H.K., Chang D.M., Hsieh S.L., Tsai P.Y., and Chen A. Decoy Receptor 3 Ameliorates an Autoimmune Crescentic Glomerulonephritis Model in Mice. J. Am. Soc. Nephrol. 18 9 (2007) 2473-2485
12. Kidoya H., Umemura M., Kawabe T., Matsuzaki G., Yahagi A., Imamura R., and Suda T. Fas ligand induces cell-autonomous IL-23 production in dendritic cells, a mechanism for Fas ligand-induced IL-17 production. J. Immunol. 175 (2005) 8024-8031
13. Kim S., McAuliffe W.J., Zaritskaya L.S., Moore P.A., Zhang L., and Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect. Immun. 72 (2004) 89-93
14. Kim S., Fotiadu A., and Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin. Immunol. 115 (2005) 286-294
15. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J.S., Perry J.W., Chen S.F., Zhou J.X., Cho Y.H., Ullrich S., Kanakaraj P., Carrell J., Boyd E., Olsen H.S., Hu G., Pukac L., Liu D., Ni J., Kim S., Gentz R., Feng P., Moore P.A., Ruben S.M., and Wei P. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16 (2002) 479-492
16. Mueller A.M., Pedre X., Kleiter I., Hornberg M., Steinbrecher A., and Giegerich G. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 159 (2005) 55-65
17. Pappu B.P., Borodovsky A., Zheng T.S., Yang X., Wu P., Dong X., Weng S., Browning B., Scott M.L., Ma L., Su L., Tian Q., Schneider P., Flavell R.A., Dong C., and Burkly L.C. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J. Exp. Med. 205 (2008) 1049-1062
18. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., Godowski P.J., Wood W.I., Gurney A.L., Hillan K.J., Cohen R.L., Goddard A.D., Botstein D., and Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (1998) 699-703
19. Rohn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., Kopf M., and Bachmann M.F. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36 (2006) 2857-2867
20. Sabelko K.A., Kelly K.A., Nahm M.H., Cross A.H., and Russell J.H. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159 (1997) 3096-3099
21. Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., and Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J. Exp. Med. 195 (2002) 1613-1624
22. Sean Riminton D., Korner H., Strickland D.H., Lemckert F.A., Pollard J.D., and Sedgwick J.D. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J. Exp. Med. 187 (1998) 1517-1528
23. Selmaj K., Papierz W., Glabinski A., and Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56 (1995) 135-141
24. Suen W.E., Bergman C.M., Hjelmstrom P., and Ruddle N.H. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med. 186 (1997) 1233-1240
25. Sung H.H., Juang J.H., Lin Y.C., Kuo C.H., Hung J.T., Chen A., Chang D.M., Chang S.Y., Hsieh S.L., and Sytwu H.K. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J. Exp. Med. 199 (2004) 1143-1151
26. Umemura M., Kawabe T., Shudo K., Kidoya H., Fukui M., Asano M., Iwakura Y., Matsuzaki G., Imamura R., and Suda T. Involvement of IL-17 in Fas ligand-induced inflammation. Int. Immunol. 16 (2004) 1099-1108
27. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Woody J.N., Hartung H.P., and Polman C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
28. Waldner H., Sobel R.A., Howard E., and Kuchroo V.K. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159 (1997) 3100-3103
29. Wan X., Shi G., Semenuk M., Zhang J., and Wu J. DcR3/TR6 modulates immune cell interactions. J. Cell. Biochem. 89 (2003) 603-612
30. Wu Y., Han B., Sheng H., Lin M., Moore P.A., Zhang J., and Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 105 (2003) 724-732
31. Wu S.F., Liu T.M., Lin Y.C., Sytwu H.K., Juan H.F., Chen S.T., Shen K.L., Hsi S.C., and Hsieh S.L. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J. Leukoc. Biol. 75 (2004) 293-306
32. Xu G., Liu D., Okwor I., Wang Y., Korner H., Kung S.K., Fu Y.X., and Uzonna J.E. LIGHT Is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J. Immunol. 179 (2007) 6901-6909
33. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., and Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274 (1999) 13733-13736